TABLE 4.
Irinotecan plasma pharmacokinetic parameters from a noncompartmental analysis
| Irinotecan | SN38 | SN38-G | |
|---|---|---|---|
| CMAX (ng/mL) | 93.9 ± 60.8 (64.8%) | 1.84 ± 1.17 (63.4%) | 5.50 ± 3.38 (61.4%) |
| TMAX (hr) | 1.97 ± 0.85 (43.3%) | 2.44 ± 1.32 (54.0%) | 3.17 ± 1.09 (34.2%) |
| AUCINF (hr•ng/mL) | 594 ± 299 (50.4%) | 16.7 ± 8.81 (52.8%) | 62.1 ± 35.4 (57.0%) |
| t1/2 (hr) | 4.38 ± 0.73 (16.6%) | 7.52 ± 2.85 (37.9%) | 8.03 ± 2.34 (29.1%) |
| CL/F (L/hr/m2) | a 130 ± 64.7 (49.9%) | N/A | N/A |
| Vz/F (L/m2) | a 794 ± 384 (48.3%) | N/A | N/A |
Abbreviations: AUCINF, area under the concentration-time curve extrapolated to infinity; CL/F, oral apparent clearance; CMAX, maximum plasma concentration; N/A, not applicable (SN38 and SN38-G are metabolites and not able to have CL/F and Vz/F properly calculated); TMAX: time to CMAX; Vz/F, volume of distribution.
a
Denotes one outlier removed from mean calculation (> 2 standard deviations above mean).